Gene · 196528
ARID2: AT-rich interaction domain 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ARID2: AT-rich interaction domain 2. Genes, record 196528. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/196528
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q68CP9 | AT-rich interactive domain-containing protein 2 | 1,835 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents29
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 6141 | Q68CP9 | Espacenet |
| JP 2025164846 A | 2025-10-30 | 20 | Q68CP9 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5891 | Q68CP9 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 14746 | Q68CP9 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5891 | Q68CP9 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 6141 | Q68CP9 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 6816 | Q68CP9 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 14746 | Q68CP9 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 14746 | Q68CP9 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 14585 | Q68CP9 | Espacenet |
1 to 10 of 29
See all 29 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,580
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ARID2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 66 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 37 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 9 | 2025 |
| R01CA113794 | The function of Snf5 (SMARCB1), an epigenetic tumor suppressor | 9 | 2025 |
| P50CA121974 | Yale SPORE in Skin Cancer | 8 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 7 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 7 | 2025 |
| R01CA172152 | Role of the SWI/SNF complex in tumor suppression | 7 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 6 | 2025 |
| P30CA196521 | The Tisch Cancer Institute - Cancer Center Support Grant | 6 | 2025 |
1 to 10 of 1,580Source NIH's project files
See all 1,580 nih grantsPapers2,393
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer. | Cancer Rep (Hoboken) | 2026 | 42817222 | PubTator, text mining | PubMed |
| Calcitriol alleviates ARID2-deficient gastric cancer metastasis via inhibition of the Wnt/β-catenin signaling pathway. | Transl Oncol | 2026 | 42771913 | PubTator, text mining | PubMed |
| ARID2 Loss Destabilizes PBAF and Drives Colorectal Cancer. | Mol Carcinog | 2026 | 42762512 | PubTator, text mining | PubMed |
| Fronto-central N200 lateralization during cue-dependent attentional orienting and response control in children with developmental dyscalculia. | Child Neuropsychol | 2026 | 42640197 | PubTator, text mining | PubMed |
| Genotypic and Phenotypic Profile of 50 Cases With Chromatin Remodeling Complexes-Related Neurological Disorders. | CNS Neurosci Ther | 2026 | 42528014 | PubTator, text mining | PubMed |
| The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer. | Clin Cancer Res | 2026 | 42507545 | PubTator, text mining | PubMed |
| The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma. | Front Immunol | 2026 | 42421952 | PubTator, text mining | PubMed |
| Fulminant extraneural metastases in MYC-amplified Group 3 medulloblastoma: a pediatric case report. | Childs Nerv Syst | 2026 | 42399488 | PubTator, text mining | PubMed |
| Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer. | Sci Rep | 2026 | 42259884 | PubTator, text mining | PubMed |
| A guide to selecting high-performing antibodies for ARID2 (UniProt ID: Q68CP9) for use in western blot, immunoprecipitation, and immunofluorescence. | F1000Res | 2026 | 42232299 | PubTator, text mining | PubMed |
1 to 10 of 2,393
See all 2,393 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/196528
GET https://conductscience.org/api/genes/v1/196528/patents?page=2